BURKIMAB: Study multicentre of optimisation of the treatment of LLA-B [acute lymphoblastic leukaemia] and the Burkitt's lymphoma in adult patients (from 15 years old).

Trial Profile

BURKIMAB: Study multicentre of optimisation of the treatment of LLA-B [acute lymphoblastic leukaemia] and the Burkitt's lymphoma in adult patients (from 15 years old).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2014

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics; Cytarabine; Filgrastim; Methotrexate
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma
  • Focus Therapeutic Use
  • Acronyms BURKIMAB
  • Most Recent Events

    • 27 Feb 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 12 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 May 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top